Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions

International Journal of Molecular Sciences(2023)10.3390/ijms241813726Source: DataRank Database

Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions is a research paper published in International Journal of Molecular Sciences (2023). On theSindex it has a DataRank of 0. It has been cited 60 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access60 citations

Download PDF

Cite:

Linked data & code

gen nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 6.89)OA: goldTopics (45)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Jin Sun Lee ORCID,Xiaojiang Cui ORCID,Yuan Yuan ORCID,Cynthia Mark ORCID

Live enrichment

PubMed:37762027 PMC:PMC10531043 OpenAlex:https://openalex.org/W4386484293

National Institutes of Health

Grant: R01CA151610

National Institutes of Health

Grant: R21CA280458

National Institutes of Health

Grant: W81XWH-18-1-0067

National Institutes of Health

Grant: 5R01CA151610-07

The Role of FOXCI in Basal-like Breast Cancer

National Institutes of Health

Grant: 1R21CA280458-01

Crosslinking-based targeted therapy for triple-negative breast cancer

FWCI

6.89

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/1422-0067/24/18/13726/pdf?version=1693981568

publisherhttps://www.mdpi.com/1422-0067/24/18/13726/pdf?version=1693981568

publisherhttps://www.mdpi.com/1422-0067/24/18/13726/pdf

journalhttps://doi.org/10.3390/ijms241813726

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37762027

Fields of Study

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchChronic Lymphocytic Leukemia Research03 medical and health sciences0302 clinical medicine

MeSH Terms

AnimalsBreast NeoplasmsCamptothecinFemaleHumansErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-2ImmunoconjugatesDrug Resistance, NeoplasmAntibodies, Monoclonal, HumanizedTriple Negative Breast Neoplasms

Keywords

Breast cancerMedicineAntibody-drug conjugateMonoclonal antibodyDrugTriple-negative breast cancerTargeted therapyCancerImmunotherapyDrug resistanceCancer researchAntibodyOncologyPharmacologyImmunologyInternal medicineBiologyAntibody–drug ConjugatesImmunoconjugatesDrug Resistance, NeoplasmHumansAnimalsFemaleBreast NeoplasmsTriple Negative Breast NeoplasmsCamptothecinReviewAntibodies, Monoclonal, HumanizedErb-b2 Receptor Tyrosine Kinases

Sustainable Development Goals

SDG 0: Good health and well-being